STRUCTURAL GENOMIX AND LILLY EXTEND SUCCESSFUL RESEARCH

Privately held Structural GenomiX today announced a three-year extension of a research and technology collaboration with Eli Lilly. In April 2003, the companies initiated a research and technology collaboration to accelerate Lilly's drug discovery programs through the application of SGX's proprietary technologies. Under the collaboration, SGX has applied its proprietary technologies to key Lilly drug targets to determine high quality crystal structures and data on target/inhibitor complexes. The three-year extension will allow this technology to continue to be applied broadly across Lilly's target portfolio.

PharmaLive (http://www.medadnews.com/News/Index.cfm?articleid=255748)